Neos Therapeutics Inc (NEOS) : Dsc Advisors scooped up 91,122 additional shares in Neos Therapeutics Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 784,704 shares of Neos Therapeutics Inc which is valued at $6,552,278.Neos Therapeutics Inc makes up approximately 4.00% of Dsc Advisors’s portfolio.
Other Hedge Funds, Including , Perceptive Advisors boosted its stake in NEOS in the latest quarter, The investment management firm added 526,876 additional shares and now holds a total of 626,876 shares of Neos Therapeutics Inc which is valued at $5,234,415. Neos Therapeutics Inc makes up approx 0.34% of Perceptive Advisors’s portfolio.Proshare Advisors reduced its stake in NEOS by selling 2,132 shares or 15.65% in the most recent quarter. The Hedge Fund company now holds 11,490 shares of NEOS which is valued at $81,579.California State Teachers Retirement System boosted its stake in NEOS in the latest quarter, The investment management firm added 300 additional shares and now holds a total of 29,115 shares of Neos Therapeutics Inc which is valued at $184,880. Falcon Point Capital added NEOS to its portfolio by purchasing 69,135 company shares during the most recent quarter which is valued at $380,243. Neos Therapeutics Inc makes up approx 0.06% of Falcon Point Capital’s portfolio.
Neos Therapeutics Inc. is a pharmaceutical company develops manufactures and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technologies. The Companys product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. It manufactures and markets generic Tussionex a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension product indicated for the relief of cough and upper respiratory symptoms associated with allergies or colds in adults and children of six years of age and older. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD and NT-0201 amphetamine XR liquid suspension for the treatment of ADHD. The company is headquartered in Grand Prairie Texas.